Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05081427 · ClinicalTrials.gov registry record

Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2

A clinical trial, sponsored by Mayo Clinic.

Completed
Registry status
17
Enrollment target

NCT05081427: Completed study, sponsored by Mayo Clinic.

NCT05081427 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05081427 has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
17 participants
Enrollment target

Study Summary

This study is a prospective, observational, single-center, short-term cross-sectional study to assess the repeatability and reproducibility of a set of specified MRI quantitative biomarkers.

Primary Outcome

Repeatability liver stiffness in kilopascals (kPa)

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2021-11-15
Est. Completion 2022-06-30
Mayo Clinic

2,844 total trials

What the finished NCT05081427 record still lists

NCT05081427 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT05081427 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05081427 about?

NCT05081427 is a clinical study titled "Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2". This study is a prospective, observational, single-center, short-term cross-sectional study to assess the repeatability and reproducibility of a set of specified MRI quantitative biomarkers.

What is the current status of trial NCT05081427?

This trial is currently completed. The enrollment target is 17 participants. The study started on 2021-11-15. Estimated completion is 2022-06-30.

Who is sponsoring clinical trial NCT05081427?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05081427, the US trial registry maintained by the National Library of Medicine. NCT05081427 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.